Skip to main content
. 2003 Dec 17;89(Suppl 3):S29–S34. doi: 10.1038/sj.bjc.6601498

Figure 3.

Figure 3

Grade III–IV toxicities in 33 patients with advanced ovarian cancer being treated with first-line sequential therapy with docetaxel 85 mg m−2 (day 1), cisplatin 75 mg m−2 (day 2) and epirubicin 60 mg m−2 (day 3) every 3 weeks for up to six cycles (Molitor et al, 2000).